bioMérieux S.A. (FRA:EYWN)

Market Cap	11.55B -12.9%
Revenue (ttm)	4.12B +8.3%
Net Income	377.90M -8.1%
EPS	3.17 -8.6%
Shares Out	n/a
PE Ratio	30.56
Forward PE	20.17
Dividend	0.90 (0.86%)
Ex-Dividend Date	Jun 9, 2025

Volume	n/a
Average Volume	11
Open	99.80
Previous Close	100.80
Day's Range	99.80 - 99.80
52-Week Range	99.80 - 130.60
Beta	n/a
RSI	26.51
Earnings Date	Feb 27, 2026

About bioMérieux

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1963
• Employees: 14,754
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EYWN

Financial Performance

In 2024, bioMérieux's revenue was 3.98 billion, an increase of 8.31% compared to the previous year's 3.67 billion. Earnings were 432.20 million, an increase of 20.86%.